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Abstract	  	  
Cardiovascular	   disease	   encompasses	   several	   diverse	   pathological	   states	   that	   place	   a	   heavy	   burden	   on	  
individual	   and	   population	   health.	   The	   aetiological	   basis	   of	   many	   cardiovascular	   disorders	   is	   not	   fully	  
understood.	  Growing	  knowledge	  of	  the	  genetic	  architecture	  underlying	  coronary	  heart	  disease,	  stroke,	  cardiac	  
arrhythmias	   and	   peripheral	   vascular	   disease	   has	   confirmed	   some	   suspected	   causal	   pathways	   in	   these	  
conditions	  but	  also	  uncovered	  many	  previously	  unknown	  mechanisms.	  Here,	  we	  consider	  the	  contribution	  of	  
genetics	  to	  the	  understanding	  of	  cardiovascular	  disease	  risk.	  We	  evaluate	  the	  utility	  and	  relevance	  of	  findings	  
from	   genome-­‐wide	   association	   studies,	   and	   explore	   the	   role	   that	   Mendelian	   randomisation	   has	   to	   play	   in	  
exploiting	  these.	  Mendelian	  randomisation	  permits	  robust	  causal	   inference	  in	  an	  area	  of	  research	  where	  this	  
has	   been	   hampered	   by	   bias	   and	   confounding	   in	   observational	   studies.	   In	   doing	   so,	   it	   provides	   evidence	   for	  
causal	  processes	  in	  cardiovascular	  disease	  that	  could	  represent	  novel	  targets	  for	  much-­‐needed	  new	  drugs	  for	  




Cardiovascular	   disease	   (CVD)	   is	   frequently	   cited	   as	   an	   illustrative	   example	   of	   a	   'complex	   disease',	   and	  
encompasses	   several	   pathological	   states	   and	   events,	   including	   hypertension,	   hyperlipidaemia,	   myocardial	  
infarction	   (MI)	   and	   stroke.	   These	   share	   many	   features	   of	   aetiology,	   pathogenesis,	   risk	   factors	   and	   clinical	  
presentation,	   but	   large	   variation	   exists	   between	   and	  within	   conventional	   disease	   categories.	   Differences	   in	  
CVD	   manifestation	   across	   a	   population	   are	   ascribed	   to	   many	   behavioural,	   environmental	   and	   genetic	  
determinants	   and	   the	   interactions	   between	   these.	   Ascertainment	   of	   the	   true	   contribution	   of	   each,	   their	  
interrelationships,	  and	  the	  relevance	  of	  these	  to	  clinical	  practice	  and	  to	   individual	  and	  population	  health	   is	  a	  
considerable	  scientific	  challenge.	  The	  genetic	  determinants	  of	  CVD	  risk	  have	  attracted	  increasing	  attention	  in	  
recent	  years	  because	  of	  their	  unique	  capacity	  to	  inform	  on	  causation,	  prediction	  and	  novel	  therapies.	  
	  
Two	  key	  scientific	  aims	  prevail	  in	  CVD	  research:	  1)	  improvement	  in	  prediction	  of	  future	  disease	  events,	  and	  2)	  
understanding	   of	   the	   pathogenic	   process	   underlying	   disease,	   and	   by	   extension,	   identification	   of	   potential	  
therapeutic	  and	  preventive	  targets.	  Existing	  methods	  for	  prediction	  of	  CVD	  events	  are	  informed	  by	  prospective	  
observational	   studies,	  within	  which	   factors	  measured	  earlier	   in	   life	  are	   found	   to	  predict	   subsequent	  disease	  
onset	  and	  progression[1–3].	  Risk	  prediction	  models	  have	  clinical	  utility	  but	  are	  by	  no	  means	  definitive,	  leaving	  
wide	  scope	  for	  improving	  the	  accuracy	  and	  reliability	  of	  prediction.	  Risk	  factors	  included	  in	  prediction	  models	  
must	   inform	   estimation	   of	   future	   risk,	   but	   need	   not	   themselves	   be	   causal	   determinants	   of	   CVD.	   As	  
observational	  studies	  continue	  to	  identify	  novel	  CVD	  risk	  factors[4],	  their	  relevance	  for	  prediction,	  aetiological	  
investigation,	  or	  both,	  must	  be	  carefully	  considered.	  Some	  important	  risk	  factors	  have,	  however,	  been	  found	  
to	  have	  both	  predictive	  and	  causal	  roles.	  Among	  these	  hyperlipidaemia[5],	  hypertension[6],	  systemic	  and	  local	  
inflammation[7,8],	   and	   hyperglycaemia[9]	   are	   arguably	   the	   most	   influential.	   While	   these	   factors	   together	  
contribute	  substantially	  to	  CVD	  pathogenesis,	  many	  of	  the	  causal	  pathways	  leading	  to	  CVD	  are	  not	  recognised	  
or	  understood.	  Existing	  pharmacological	   therapeutic	  and	  preventive	  strategies	  considerably	   reduce	  CVD	  risk,	  
and	   generally	   target	   well-­‐characterised	   causal	   pathways,	   such	   as	   blood	   lipids,	   blood	   pressure	   and	  
hyperglycaemia.	  However,	  even	  with	  optimal	  treatment	  with	  current	  drugs,	  a	  sizeable	  proportion	  of	  individual	  
and	   population	   risk	   persists[10],	   leaving	   a	   need	   for	   novel	   treatments,	   and	   identification	   of	   additional	  
pathogenic	  processes	  may	  elucidate	  targets	  for	  new,	  or	  existing	  drugs.	  Genetic	  research	  offers	  opportunities	  
for	   investigating	   prediction,	   aetiology	   and	   novel	   therapeutics,	   which	   we	   review	   below	   with	   a	   focus	   on	  




Identifying	  genetic	  risk	  factors	  
Much	   of	   the	   foundation	   of	   cardiovascular	   genetics	   has	   grown	   from	   investigation	   and	   understanding	   of	   the	  
familial	   hyperlipidaemias.	   Familial	   hypercholesterolaemia	   (FH)	   is	   an	   autosomal	   dominant	   disease	   with	   a	  
frequency	  of	  between	  1/500	  and	  1/300	  members	  of	  the	  general	  population.	  It	  is	  caused	  by	  rare	  variants	  in	  the	  
genes	   encoding	   the	   low-­‐density	   lipoprotein	   cholesterol	   (LDL-­‐C)	   receptor	   (LDLR	   chromosome	   19p13.2),	  
apolipoprotein	   B	   (APOB,	   chromosome	   2p24),	   and	   proprotein	   convertase	   subtilisin/kexin	   type	   9	   (PCSK9,	  
chromosome	   1p32.2)[11].	   Patients	   with	   FH	   have	   very	   high	   plasma	   LDL-­‐C	   concentrations,	   accelerated	  
atherogenesis	  and	  early	  onset	  of	  CVD	  events,	  in	  particular	  coronary	  heart	  disease	  (CHD).	  Concerted	  efforts	  in	  
family	   screening	   and	   technological	   developments	   such	   as	   next-­‐generation	   sequencing	   of	   whole	   exomes	  
continue	   to	   identify	   new	   FH-­‐causing	   genes[12–14],	   many	   of	   which	   are	   potential	   candidates	   for	   the	  
development	   of	   novel	   therapies.	   Investigation	   of	   FH	   genetics	   has	   made	   important	   contributions	   to	  
understanding	  of	  CVD	  pathogenesis,	  however	  these	  rare,	  highly	  penetrant	  mutations	  are	  responsible	  for	  only	  a	  
small	  fraction	  of	  the	  global	  burden	  of	  CVD	  and	  leave	  many	  aetiological	  questions	  unanswered.	  	  
Identification	   of	   common	   genetic	   variants	   associated	   with	   CVD	   risk	   and	   related	   biomarkers,	   and	   their	  
exploitation	   for	   translation	  has	  been	   the	   focus	  of	  genetic	   research	   in	   this	   field	   since	   the	  advent	  of	  genome-­‐
wide	  association	  (GWA)	  studies[15].	  GWA	  studies	  seek	  to	  identify	  genetic	  variants	  across	  the	  genome	  that	  are	  
associated	  with	  differences	  in	  CVD	  risk	  or	  CVD-­‐related	  biomarkers,	  and	  have	  generated	  a	  broad	  and	  complex	  
body	  of	  evidence	  for	  the	  genetic	  contribution	  to	  CVD	  risk[16].	  In	  general,	  these	  variants	  are	  common	  and	  have	  
small	   phenotypic	   effects.	   For	   example,	   odds	   ratios	   for	   MI	   associated	   with	   a	   GWA	   study-­‐identified	   genetic	  
variant	  are	  typically	  in	  the	  order	  of	  1.10	  to	  1.20.	  GWA	  studies	  consequently	  require	  very	  large	  samples	  of	  tens	  
of	   thousands	   of	   individuals	   to	   achieve	   sufficient	   statistical	   power,	   with	   data	   from	   several	   samples	   often	  
combined	  using	  meta-­‐analysis[17]	  (Table	  1).	  	  
	  
Coronary	  artery	  disease	  and	  its	  related	  biomarkers	  
Several	  GWA	  studies	  of	  CHD	  have	   identified	   common	  variants	   at	   a	  number	  of	   genomic	   loci	   in	   samples	  now	  
including	  many	  thousands	  of	  cases	  and	  controls[17–19]	  (Table	  1).	  Some	  identified	  loci	  are	  involved	  in	  known	  
pathogenic	  pathways,	   including	  those	  related	  to	  blood	   lipids	   (LDLR,	  PCSK9,	  APOE).	  Also	   identified	  have	  been	  
some	   less	   predictable	   loci	   -­‐	   ABO	   (chromosome	   9q34.2),	   involved	   in	   determining	   ABO	   blood	   type;	   IL6R	  
(chromosome	  1q21)	  -­‐	  encoding	  the	  proinflammatory	  interleukin-­‐6	  receptor[17];	  and	  a	  variant	  in	  an	  intergenic	  
region	  of	  chromosome	  9	  (9p21.3)	  of	  which	  the	  function	  and	  biological	  relevance	   is	  now	  under	  close	  scrutiny	  
but	   remains	   uncertain[20,21].	   In	   addition	   to	   risk	   of	   disease	   events,	   GWA	   studies	   have	   examined	   genetic	  
determinants	  of	  conventional	  CVD	  risk	  factors,	  including	  blood	  pressure[22],	  lipids[23],	  body	  composition[24],	  
and	  smoking	  behaviour[25].	  These	  studies	  have	  added	  to	  our	  understanding	  of	  CVD	  pathogenesis,	  and	  have	  
begun	   to	   highlight	   potential	   drug	   targets	   for	   disease	   prevention.	   Notably,	   variants	   in	   	   PCSK9	   were	   first	  
identified	   as	   causes	   of	   FH	   and	   were	   subsequently	   identified	   by	   general	   population	   GWA	   studies	   of	   LDL-­‐C	  
concentration	  and	  CHD	  risk.	  PCSK9	  is	  the	  target	  of	  novel	   lipid-­‐lowering	  drugs	  developed	  following	  the	  GWAS	  




GWA	  studies	  of	  heart	  rhythm	  disorders	  have	  identified	  a	  number	  of	  dysrhythmia-­‐associated	  loci.	  As	  might	  be	  
expected,	   many	   of	   the	   reported	   variants	   are	   in	   genes	   encoding	   ion	   channels.	   For	   example,	   variants	   in	   the	  
potassium	   channel-­‐encoding	   genes	   HCN4	   and	   KCNN3	   have	   been	   associated	   with	   risk	   of	   atrial	   fibrillation	  
(AF)[26,27].	   In	   addition	   to	   studies	  of	   risk	  of	   specific	   arrhythmia	  diagnoses,	  GWA	  studies	  of	  quantitative	  ECG	  
traits	   have	   also	   yielded	   important	   results.	   Variants	   in	   the	   gene	   encoding	   voltage-­‐gated	   sodium	   channels	  
(SCN5A	  and	  SCN10A)	  have	  been	  found	  to	  associate	  with	  QRS	  complex	  duration[28–30],	  and	  PR	  interval[28,31–
33].	  Reported	  by	  a	  number	  of	  GWA	  studies	   for	   its	  association	  with	  QT	  segment	  duration	  are	  variants	  at	   the	  
NOS1AP	   locus	  encoding	  nitric	  oxide	  synthase	  1	  adaptor	  protein[32–34],	   for	  which	  a	   role	   in	  calcium	  channel-­‐
mediated	   myocardial	   repolarisation	   has	   been	   proposed[35].	   These	   findings,	   while	   confirming	   previously	  
suspected	  aetiological	  pathways	  may	  suggest	  promising	  targets	  for	  novel	  anti-­‐arrhythmic	  drugs.	  
	  
Heart	  failure	  
'Heart	   failure'	   encompasses	   a	   diverse	   group	   of	   phenotypes	   with	   different,	   though	   often	   overlapping	  
aetiologies.	   This	   diversity	  has	  presented	  a	   challenge	   to	   those	   investigating	  heart	   failure	   genetics	   as	  detailed	  
phenotyping	   is	  required	  to	  ensure	  accurate	  case	  ascertainment,	  and	  relatively	  few	  studies	  are	  reported.	   In	  a	  
collaborative	  GWA	   study	   taking	   incident	  heart	   failure	   as	   a	   single	  disease	  entity	   in	   nearly	   24,000	   individuals,	  	  
variants	   were	   reported	   near	   the	  USP3	   locus	   in	   people	   of	   European	   ancestry	   and	   LRIG3	   in	   those	   of	   African	  
ancestry[36].	   Of	   note,	   no	   other	   variants	   in	   that	   analysis	   met	   the	   genome-­‐wide	   threshold	   for	   statistical	  
significance	  (p<1x10-­‐7),	  possibly	  as	  a	  result	  of	  between-­‐	  and	  within-­‐study	  heterogeneity.	  Investigation	  of	  heart	  
failure-­‐related	   phenotypes	   has	   also	   yielded	   limited	   success,	   with	   only	   a	   handful	   of	   loci	   identified	   for	   their	  
associations	   with	   dilated	   cardiomyopathy	   (BAG3,	   ZBTB17)[37]	   and	   left	   ventricular	   mass	   (RAI14,	   CD36)[38],	  
though	   these	  were	   reported	   in	   relatively	   small	   samples.	  One	  GWA	   study	  of	   circulating	  N-­‐terminal	   pro-­‐brain	  
natriuretic	  peptide	  (NT-­‐proBNP),	  a	  biomarker	  of	  heart	  failure,	  reported	  associations	  	  at	  three	  loci,	  including	  the	  
chloride	   channel,	  CLCN6[39].	  Heart	   failure	   is	   an	   area	  where	   larger	   samples	   of	   finely	   phenotyped	   individuals	  
may	   be	   needed	   to	   advance	   our	   understanding	   of	   the	   underlying	   genetics	   of	   its	   multiple	   constituent	  




Valvular	  heart	  disease	  
Heart	  valve	  disease	  has	  been	   investigated	  by	  relatively	   few	  studies,	  but	  provides	  an	   important	   illustration	  of	  
the	  investigative	  pathway	  from	  GWA	  study	  to	  Mendelian	  randomisation	  (MR)	  analysis.	  A	  2013	  GWA	  study	  of	  
aortic	   and	  mitral	   valve	   calcification	   reported	  associations	  of	   a	   variant	   at	   the	  LPA	   locus	  with	  both	   circulating	  
lipoprotein(a)	   (Lp(a))	   concentrations	   	   and	   aortic	   valve	   calcification[40].	   The	   authors	   also	   reported	   an	   MR	  
analysis	   demonstrating	   that	   genetically	   raised	   Lp(a)	   concentrations	   were	   associated	   with	   aortic	   valve	  
calcification,	   and	   supporting	   a	   causal	   role	   for	   Lp(a)	   in	   this	   complex	   phenotype.	   Similar	   findings	   were	  
subsequently	   elsewhere[41,42],	   and	   the	   variants	   in	   LPA	   have	   also	   been	   reported	   by	   GWA	   studies	   of	  
CHD[18,43].	  Lp(a)	  appears,	  therefore,	  to	  be	  a	  causal	  determinant	  of	  more	  than	  one	  area	  of	  CVD,	  and	  offers	  a	  
potentially	  important	  therapeutic	  opportunity.	  
	  
Stroke	  	  
Findings	  from	  GWA	  studies	  of	  stroke	  have	  been	  less	  fruitful	  than	  for	  CHD,	  with	  a	  relative	  paucity	  of	  disease-­‐
associated	   variants.	   Notably,	   several	   loci	   showing	   genome-­‐wide	   associations	  with	   ischaemic	   stroke	   are	   also	  
associated	  with	  CHD.	  Among	  these	  are	  the	  chromosome	  9p21	  locus	  and	  ABO	  (chr9q34.2),	  both	  of	  which	  have	  
been	   reported	  by	  a	  number	  of	  CHD	  GWA	  studies,	   and	  which	   show	  directionally	   concordant	  effects	  on	  both	  
disease	  phenotypes[44].	  Stroke	  presents	  a	  challenge	  similar	  to	  that	  of	  heart	  failure,	  encompassing	  a	  range	  of	  
very	   different	   clinical	   phenotypes,	   broadly	   grouped	   as	   ischaemic	   stroke	   (including	   	   embolic,	   atherosclerotic,	  
large	   and	   small	   vessel	   subtypes),	   and	   intracranial	   haemorrhage.	   The	   differences	   in	   the	   phenotypes	   and	   the	  
relative	   difficulty	   in	   precisely	   determining	   their	   aetiology	   has	  made	   investigation	   of	   stroke	   in	   GWA	   studies	  
more	  challenging.	  A	  number	  of	  important	  loci	  with	  large	  effects	  on	  stroke	  have,	  however,	  been	  identified[45].	  	  
	  
Abdominal	  aortic	  aneurysm	  
Abdominal	  aortic	  aneurysm	  (AAA)	  is	  a	  common	  disease	  of	  later	  life,	  which,	  if	  untreated,	  can	  rupture	  with	  high	  
resultant	  mortality[46].	  The	  genetic	  architecture	  AAA	  has	  been	  investigated	  using	  GWA	  studies,	  although	  these	  
emerged	  some	  years	  after	  the	  first	  studies	  of	  CHD.	  The	  chromosome	  9p21.3	  region,	  strongly	  associated	  with	  
CHD[47],	   has	   been	   shown	   also	   to	   contribute	   to	   AAA	   development	   with	   an	   associated	   excess	   risk	   of	  
approximately	  30%	  per	  allele[48],	  a	  finding	  that	  has	  been	  replicated	  in	  several	  subsequent	  studies[49].	  Larger,	  
later	  GWA	  studies	  have	  reported	  additional	  AAA-­‐associated	  variants	  at	  the	  DAB21P	  locus	  (chr9q33)[50],	  LRP1	  
(chr12q13.3)[51]	  and	  LDLR	  (chr	  19p13.2)[52],	  and	  a	  large	  candidate	  gene	  study	  using	  variants	  in	  IL6R	  (chr1q21)	  
confirmed	   a	   role	   in	   AAA	   for	   signalling	   at	   the	   interleukin-­‐6	   (IL-­‐6)	   receptor[53].	   Current	   conventional	  
management	  of	  AAA	  comprises	  watchful	  waiting	  for	  low	  risk	  aneurysms,	  and	  endovascular	  interventions	  and	  
open	  surgical	  repair	  for	  those	  at	  higher	  risk	  of	  rupture;	  there	  are	  no	  definitive	  pharmacotherapeutic	  options.	  
As	  the	  genetic	  determinants	  of	  AAA	  has	  become	  clearer,	  potential	  novel	  therapeutic	  targets	  have	  emerged.	  Of	  
particular	   note	   are	   the	   IL-­‐6	   receptor,	   for	  which	   a	   routinely	   prescribed	   inhibitor	   drug	   exists,	   and	   cholesterol	  
pathways,	  which	   can	  be	  modified	  using	   a	   range	  of	   lipid-­‐lowering	   agents.	   Findings	   from	  genetic	   studies	  may	  
help	   to	   prioritise	   new	   targets	   for	   drugs	   that	  may	   help	   reduce	   risk	   of	   rupture	   in	   patients	  who	   do	   not	  meet	  
prevailing	  criteria	  for	  interventional	  management.	  
	  
Emerging	  approaches	  to	  CVD	  genetic	  discovery	  
Methods	  used	  to	  discover	  novel	  CVD-­‐related	  genetic	  variants	  are	  beginning	  to	  shift	  away	  from	  the	   'classical'	  
GWA	   study,	   in	   a	   move	   driven	   principally	   by	   technological	   advances.	   The	   rapidly	   declining	   price	   of	   whole	  
genome	   or	   exome	   sequencing[54]	   offers	   new	  means	   for	   ultrafine	   dissection	   of	   the	   genetic	   architecture	   of	  
disease	  in	  large	  numbers	  of	  individuals.	  As	  large-­‐scale	  sequencing	  projects	  progress	  (e.g.	  UK	  100,000	  Genomes	  
project	   www.genomicsengland.co.uk/the-­‐100000-­‐genomes-­‐project),	   these	   data	   may	   reveal	   novel,	   rarer	  
genetic	   determinants	   of	   CVD	   risk.	   Furthermore,	   the	   range	   of	   available	   phenotypes	   continues	   to	   expand.	  
Proteomic,	   metabolomic	   and	   lipidomic	   technology	   provides	   high-­‐resolution	   CVD	   biomarkers	   of	   which	   the	  
genetic	   foundations	   can	   be	   investigated.	   The	   profile	   of	   individuals	   included	   in	   genetic	   studies	   is	   also	  
transforming.	   Early	   GWA	   studies	   were	   largely	   restricted	   to	   individuals	   of	   European	   ancestry.	   In	   the	   USA,	  
cohorts	   including	   people	   of	   African	   and	   Hispanic	   ancestry	   are	   increasingly	   reporting	   genetic	   findings,	   and	  
investigators	  in	  China,	  Japan	  and	  Korea	  are	  also	  publishing	  at	  an	  growing	  rate.	  All	  these	  developments	  provide	  
opportunities	  to	  broaden	  and	  deepen	  our	  understanding	  of	  CVD	  through	  genetics.	  
Below,	  we	  explore	  how	  recent	  findings	  are	  being	  exploited	  in	  translational	  cardiovascular	  research.	  
	  
Genetics	  and	  risk	  prediction	  
Could	  genetics	  add	  value	  to	  conventional	  risk	  prediction	  strategies?	  
CVD	   risk	  prediction	   tools	   currently	   in	   routine	   clinical	   use	   are	  based	  on	   findings	   relating	   to	   conventional	   risk	  
factors	   such	  as	   age,	   sex,	   smoking	   status	   and	  blood	   lipids	   from	  prospective	  observational	   studies[1,2].	  While	  
these	   perform	   with	   reasonable	   accuracy,	   none	   has	   perfect	   specificity	   or	   sensitivity.	   Pursuit	   of	   improved	  
prediction	  is	  ongoing,	  and	  use	  of	  genetic	  data	  has	  been	  proposed	  as	  a	  means	  of	  achieving	  this[55].	  
Attempts	   have	   been	   made	   to	   demonstrate	   the	   added	   value	   of	   incorporating	   genetic	   information	   into	  
prediction	  models.	   These	  have	   largely	   involved	  a	   composite	  model	   of	   conventional	   and	   genetic	   risk	   factors,	  
with	   the	   hypothesis	   that	   the	   genetic	   data	   will	   account	   for	   a	   sufficient	   proportion	   of	   unexplained	   risk	   to	  
improve	  predictive	  utility.	  Integrating	  personal	  genomic	  information	  into	  conventional	  clinical	  assessment	  was	  
shown	   to	   have	   merit	   for	   improving	   prediction	   in	   a	   single	   individual[56],	   but	   the	   yield	   of	   population-­‐based	  
studies	  using	  multi-­‐locus	  predictive	  gene	  scores	  has	  been	  modest	  and	  inconsistent[57–62].	  The	  reasons	  for	  this	  
failure	   are	   not	   yet	   clear.	   One	   possibility	   is	   that	   the	  majority	   of	   CVD-­‐associated	   variants	   identified	   by	   GWA	  
studies	  influence	  disease	  risk	  through	  effects	  on	  variables	  already	  included	  in	  conventional	  prediction	  models,	  
such	  as	  blood	  lipids.	  Another	  is	  that	  common	  genetic	  variants	  generally	  have	  such	  modest	  phenotypic	  effects	  
that	   these	   are	   unable	   to	   contribute	   meaningfully	   to	   clinical	   practice	   where	   larger	   effects	   are	   sought.	   One	  
strategy	  for	  overcoming	  this	  is	  to	  combine	  information	  from	  a	  number	  of	  CHD-­‐associated	  SNPs	  in	  a	  genetic	  risk	  
score[63]	  (discussed	  below).	  Despite	  early	  optimism	  for	  a	  role	  for	  genetics	  in	  CVD	  prediction,	  this	  has	  not	  yet	  
become	   a	   reality	   in	   routine	   practice.	   Commercial	   offerings	   of	   direct-­‐to-­‐consumer	   personalised	   genetic	  
prediction	  burgeoned	  in	  the	  years	  immediately	  following	  the	  completion	  of	  early	  GWA	  studies,	  but	  have	  now	  
fallen	   from	   favour	  with	   both	   consumers	   and	   regulators[64].	   The	   rapidly	   falling	   price	   of	  whole	   genome	   and	  
exome	  sequencing	  may,	  however,	  facilitate	  greater	  success	  in	  this	  field	  and	  allow	  more	  successful	  prediction.	  
	  
Mendelian	  randomisation	  in	  CVD	  
Introduction	  to	  Mendelian	  randomisation	  
MR	  uses	  genetic	  data	  to	  dissect	  the	  roles	  of	  CVD-­‐associated	  risk	  factors,	  and	  particularly	  to	  separate	  those	  
merely	  marking	  the	  presence	  or	  advent	  of	  disease	  from	  those	  with	  a	  causal	  contribution[65,66].	  MR	  exploits	  
unique	  properties	  of	  genotype	  to	  enable	  robust	  causal	  inference,	  often	  in	  settings	  where	  this	  would	  otherwise	  
be	  impossible.	  The	  traditional	  benchmark	  test	  of	  causality	  is	  the	  randomised	  controlled	  trial	  (RCT),	  which	  
measures	  the	  effects	  of	  an	  exposure-­‐modifying	  intervention	  on	  disease	  risk	  or	  related	  biomarkers.	  The	  RCT	  
framework	  permits	  causal	  inference	  by	  virtue	  of	  three	  key	  features	  of	  its	  design:	  1)random	  allocation	  to	  
intervention	  or	  control	  groups,	  which	  avoids	  confounding;	  2)	  blinding,	  which	  avoids	  bias;	  and,	  3)	  and	  the	  act	  of	  
intervention	  with	  prospective	  follow-­‐up,	  which	  avoids	  reverse	  causation.	  Such	  trials	  have	  helped	  to	  confirm	  or	  
refute	  the	  causal	  role	  of	  proposed	  risk	  factors	  in	  a	  number	  of	  complex	  disease,	  e.g.	  low-­‐density	  lipoprotein	  
cholesterol	  (LDL-­‐C)[67]	  and	  blood	  pressure[68]	  as	  causal	  mediators	  of	  coronary	  heart	  disease	  risk,	  and	  to	  
finding	  no	  evidence	  for	  a	  causal	  role	  for	  antioxidant	  supplements	  in	  cardiovascular	  disease	  prevention[69].	  	  
MR	  offers	  a	  natural	  parallel	  to	  the	  RCT	  (Figure	  1a),	  with	  similar	  features	  allowing	  causal	  inference.	  Random	  
allocation	  of	  alleles	  at	  conception	  which,	  according	  to	  Mendel's	  second	  law	  of	  independent	  assortment	  are	  
independent	  from	  each	  other,	  mirrors	  the	  randomisation	  in	  the	  RCT[70,71].	  Potential	  confounders	  are	  
distributed	  equally	  between	  different	  genotype	  groups	  for	  a	  given	  variant,	  such	  that	  any	  observed	  phenotypic	  
associations	  of	  the	  variant	  can	  be	  deemed	  direct	  consequences	  of	  that	  mutation	  and	  free	  of	  confounding.	  
Furthermore,	  genotype	  exerts	  a	  longitudinal	  action	  throughout	  life	  from	  conception,	  and	  there	  is	  a	  
unidirectional	  flow	  of	  biological	  influence	  from	  DNA	  sequence,	  through	  transcription	  and	  protein	  synthesis	  to	  
more	  complex	  phenotypes.	  These	  features	  together	  help	  to	  overcome	  the	  phenomenon	  of	  reverse	  causation	  
in	  which	  a	  supposed	  causal	  factor	  of	  disease	  is	  in	  reality	  a	  consequence	  of	  the	  disease	  process	  itself.	  Finally,	  
individuals	  are	  largely	  unaware	  of	  their	  genotype	  at	  a	  given	  locus,	  which	  replicates	  blinding	  used	  in	  RCTs.	  In	  an	  
MR	  study,	  common	  genetic	  variants	  (usually	  single	  nucleotide	  polymorphisms,	  SNPs)	  associated	  with	  the	  
biomarker	  or	  exposure	  of	  interest	  are	  used	  as	  the	  'intervention'.	  The	  biomarker	  or	  exposure	  may	  be	  an	  
endogenous	  factor	  such	  as	  LDL-­‐C	  or	  body	  mass	  index	  (BMI),	  or	  an	  exogenous	  or	  environmental	  exposure	  such	  
as	  alcohol	  consumption.	  Genetic	  variants	  associated	  with	  such	  a	  risk	  factor	  are	  used	  as	  its	  proxies,	  or	  
instruments	  (Figure	  1b).	  Associations	  of	  the	  genetic	  instrument	  with	  disease	  risk	  or	  presence	  of	  another	  
outcome	  phenotype	  can	  be	  interpreted	  as	  supporting	  a	  causal	  role	  for	  the	  risk	  factor	  in	  those	  outcomes.	  	  
Investigating	  causation	  in	  CVD	  using	  Mendelian	  randomisation	  	  
MR	  has	  been	  used	  extensively	  to	  address	  important	  aetiological	  uncertainties	  in	  CVD,	  and	  MR	  studies	  of	  CVD	  
risk	   factors	   provide	   clear	   illustrations	   of	   the	   utility	   of	   the	   technique.	   Genetic	   determinants	   of	   LDL-­‐C	  
concentration	  have	  been	   shown	   to	   causally	   associated	  with	  higher	  CHD	   risk	   in	  proof-­‐of-­‐concept	  MR	   studies	  
confirming	   existing	   evidence	   from	   randomised	   trials	   of	   lipid-­‐lowering	  medication	   [72,73].	   Furthermore,	   the	  
clear	   observational	   relationship	   of	   higher	   lipoprotein	   (a)	   concentrations	   with	   CHD	   risk	   was	   shown	   by	   MR	  
studies	  to	  be	  causal	  [74,75].	  More	  controversially,	  MR	  has	  been	  used	  to	  dissect	  the	  relationships	  of	  circulating	  
HDL-­‐C	  and	   triglycerides	  with	  CHD	   risk.	   Findings	  have	  been	  difficult	   to	   interpret	  because	  of	   the	  challenges	   in	  
selecting	   genetic	   instruments	   that	   associate	   specifically	   with	   the	   lipid	   fraction	   of	   interest.	   A	   variant	   in	   the	  
APOA5	   gene	   (chr11q23)	  associated	  with	  both	  higher	   triglyceride	   levels	  and	  CHD	  risk,	   implicated	   triglyceride-­‐
mediated	   pathways	   in	   the	   aetiology	   of	   CHD[76].	   When	   a	   genetic	   risk	   score	   (GRS)	   composed	   of	   several	  
triglyceride-­‐associated	   variants	   was	   used	   as	   the	   MR	   instrument,	   the	   apparent	   association	   between	   higher	  
triglycerides	  and	  CHD	  risk	  was	  attenuated	  after	  adjustment	  for	  lipid-­‐related	  covariates[77,78].	  With	  novel	  HDL-­‐
C-­‐raising	  drugs	  in	  advanced	  stages	  of	  development[79],	  greatest	  interest	  has	  fallen	  on	  the	  causal	  role	  of	  HDL-­‐C.	  
MR	  studies	  have	  used	  single	  HDL-­‐C-­‐associated	  variants	  in	  a	  range	  of	  different	  genes	  but	  report	  no	  association	  
of	  any	  of	  these	  with	  CHD	  risk	  [80–82],	  a	  finding	  replicated	  with	  an	  HDL-­‐C	  GRS	  [77,82].	  Together,	  these	  findings	  
appear	  to	  argue	  against	  a	  causal	  role	   for	  HDL-­‐C	   in	  CHD,	  however	  the	  many	  determinants	  of	  HDL-­‐C	   level	  and	  
function	  complicate	  their	   interpretation	  and	   leave	  open	  the	  possibility	  of	  both	  a	  causal	   role	  and	  a	  beneficial	  
effect	  of	  HDL-­‐C-­‐raising	  therapies.	  	  
The	  role	  of	  inflammation	  in	  CVD	  has	  been	  addressed	  using	  MR,	  with	  high	  profile	  examples	  involving	  C-­‐reactive	  
protein	  (CRP)	  and	  IL-­‐6.	  The	  strong	  epidemiological	  association	  between	  higher	  plasma	  CRP	  concentrations	  and	  
CHD	  risk[7],	  and	  the	  long-­‐held	  pathophysiological	  hypothesis	  of	  atherosclerosis	  as	  an	  inflammatory	  disease[83]	  
suggested	  that	  CRP	  may	  itself	  cause	  CHD.	  Variants	   in	  the	  gene	  encoding	  CRP	  (CRP	  1q23.2)	  associate	  strongly	  
with	  CRP	  concentrations,	  but	  are	  not	  associated	  with	  CHD	  risk[84],	  providing	  strong	  evidence	  that	  CRP	  merely	  
marks	  the	  presence	  of	  atherosclerotic	  disease	  rather	  than	  contributing	  to	  its	  development.	  Interpretation	  here	  
is	  simpler	  than	  for	  the	  lipid	  studies	  described	  above,	  since	  the	  protein	  CRP	  is	  the	  sole	  product	  of	  the	  CRP	  gene	  
and	   has	   no	   other	   direct	   determinants.	   Causal	   roles	   for	   other	   inflammation	   markers	   have,	   however,	   been	  
demonstrated.	  Like	  CRP,	  higher	  concentrations	  of	  IL-­‐6	  are	  associated	  with	  CHD	  risk[8],	  and	  importantly,	  the	  IL-­‐
6	  receptor	  (IL-­‐6R)	  is	  the	  target	  of	  an	  existing	  drug	  used	  to	  treat	  rheumatoid	  arthritis[85].	  Variants	  in	  the	   IL6R	  
gene	   (1q21),	   encoding	   the	   IL-­‐6R,	   influence	   IL-­‐6	   signalling	   and	   have	   been	   shown	   to	   associate	   with	   CHD	  
risk[86,87].	  These	  findings	  demonstrated	  for	  the	  first	  time	  a	  causal	  role	  for	  an	  inflammatory	  mediator	  in	  CHD,	  
and	  highlighted	  the	  IL-­‐6R	  as	  a	  promising	  drug	  target	  for	  CHD	  prevention.	  
MR	  has	  been	  used	   to	   investigate	   the	   relevance	  of	  more	   complex	   risk	   factors	   in	  CVD.	   Studies	   using	   the	  GRS	  
approach	   have	   reported	   inconsistent	   estimates	   of	   the	   causal	   role	   of	   BMI	   in	   CHD[88,89],	   despite	   clear	  
associations	  with	  higher	  risk	  of	  type	  2	  diabetes	  (T2D).	  Observational	  studies	  suggest	  a	  non-­‐linear	  relationship	  
between	  alcohol	   consumption	   (a	  behavioural	   risk	   factor)	   and	  CHD	   risk,	  with	   an	   apparent	  benefit	   associated	  
with	  light-­‐to-­‐moderate	  consumption[90].	  Genetic	  variants	  that	  associate	  strongly	  with	  alcohol	  consumption	  in	  
populations	   of	   European	   ancestry	   are,	   however,	   associated	   with	   higher	   CHD	   risk,	   with	   a	   relationship	   that	  
remained	   constant	   across	   all	   categories	   of	   alcohol	   consumption[91].	   These	   genetic	   findings	   imply	   that	   the	  
observed	  non-­‐linear	   relationship	  of	   alcohol	  with	  CHD	   risk	   is	   a	   consequence	  of	   confounding	  and	  any	   level	  of	  
alcohol	  consumption	  leads	  to	  higher	  CHD	  risk.	  
	  
Validating	  CVD	  drug	  targets	  using	  Mendelian	  randomisation	  
The	  properties	  of	  MR	  that	  allow	  causal	  inference	  as	  described	  above	  can	  be	  exploited	  for	  the	  validation	  of	  drug	  
targets.	  Since	  the	  MR	  model	  is	  viewed	  as	  a	  natural	  'RCT',	  variants	  in	  a	  gene	  encoding	  and	  influencing	  the	  level	  
or	  function	  of	  a	  protein	  drug	  target	  can	  be	  used	  as	  naturally	  occurring	  'interventions'	  with	  which	  to	  investigate	  
the	   consequences	   of	  modulating	   that	   target	   pharmacologically.	   Since	   the	  majority	   of	   known	   and	   proposed	  
drug	   targets	   are	   proteins[92]	   and	   SNPs	   in	   protein-­‐coding	   regions	   occur	   frequently	   across	   the	   genome,	   this	  
approach	  is	  broadly	  practicable.	  In	  the	  example	  of	  the	  IL-­‐6	  receptor	  described	  above,	  close	  concordance	  was	  
noted	  between	  the	  drug	  tocilizumab	  that	  inhibits	  IL-­‐6	  receptor	  signalling	  and	  variants	  in	  its	  encoding	  gene	  in	  
their	  effects	  on	  biomarkers	  of	  inflammation	  and	  risk	  of	  CHD[86]	  and	  abdominal	  aortic	  aneurysm[53].	  From	  this	  
was	  drawn	  the	  inference	  that	  the	  IL-­‐6	  receptor	  represents	  a	  potentially	  valuable	  drug	  target	  for	  prevention	  of	  
these	  two	  important	  diseases.	  The	  MR	  approach	  has	  also	  been	  used	  to	  predict	  the	  outcome	  of	  ongoing	  RCTs.	  
Secretory	   phospholipase	   A2	   (sPLA2)-­‐IIA	   has	   been	   identified	   as	   a	   potential	   target	   for	   CHD	   prevention.	   An	  
inhibitor	   of	   the	   enzyme,	   varespladib,	   was	   pursued	   until	   the	   phase	   III	   RCT	   stage[93],	   which	  was	   abandoned	  
prematurely	  on	  grounds	  of	   insufficient	  efficacy	   for	  CHD	  prevention.	  An	  MR	  study	  using	  variants	   in	   the	  gene	  
encoding	   sPLA2-­‐IIA	   (PLA2G2A,	   chr	   1p35)	   demonstrated	   a	   similar	   lack	   of	   effect	   on	   CHD[94],	   which	   was	  
corroborated	  by	  the	  subsequently	  published	  trial	  findings[95].	  
In	  addition	  to	   investigating	  main	  therapeutic	  effects,	  MR	  has	  been	  used	  to	  explore	  adverse	  drug	  effects.	  The	  
cholesteryl	   ester	   transfer	   protein	   (CETP)	   inhibitor	   torcetrapib	   was	   designed	   to	   raise	   circulating	   HDL-­‐C	  
concentrations	   in	   the	   hope	   that	   this	   would	   reduce	   CHD	   risk[96].	   A	   large	   phase	   III	   RCT	   of	   torcetrapib	   was,	  
however,	  halted	  early	  because	  of	   excess	   cardiovascular	  mortality	   in	   the	   torcetrapib-­‐treated	  arm,	  which	  was	  
thought	  to	  have	  resulted	  from	  an	  increase	  in	  blood	  pressure	  in	  those	  patients[97].	  With	  other	  CETP	  inhibitors	  
at	   that	   time	   in	   advanced	   development,	   concern	  was	   high	   that	   the	   hypertensive	   effect	   of	   torcetrapib	  was	   a	  
class-­‐wide,	   on-­‐target	   effect	   of	   the	   drug	   likely	   to	   be	   shared	  by	   the	  other	   agents.	   In	   a	   subsequent	  MR	   study,	  
variants	   in	   the	  CETP	   gene	   (chr	  16q2)	  were	   strongly	  associated	  with	  HDL-­‐C	  but	  not	  with	  differences	   in	  blood	  
pressure,	   suggesting	   that	   the	   effects	   observed	   with	   torcetrapib	   were	   off-­‐target,	   molecule-­‐specific	   effects	  
unlikely	  to	  be	  shared	  by	  the	  other	  CETP	  inhibitor	  drugs[98].	  As	  a	  second	  example,	  the	  modestly	  increased	  risk	  
of	  T2D	  with	  statin	  treatment	  observed	  in	  RCTs[99,100]	  raised	  the	  question	  of	  whether	  this	  was	  an	  on-­‐	  or	  off-­‐
target	  effect	  of	  the	  drugs;	  that	   is,	  whether	  the	  dysglycaemic	  effect	  was	  a	  direct	  consequence	  of	   inhibition	  of	  
HMG-­‐CoA,	  the	  intended	  target	  of	  statins.	  Again,	  using	  the	  MR	  approach,	  variants	  in	  the	  gene	  encoding	  HMG-­‐
CoA	  reductase	   (HMGCR,	   chr	  5q13.3)	  associated	  with	   lower	  LDL-­‐C	  were	  used	  as	  proxies	   for	   statin	   treatment.	  
Both	  statin	  treatment	  and	  the	  genetic	  variants	  were	  associated	  with	  higher	  T2D	  risk	  and	  higher	  bodyweight,	  
and	  the	  genetic	  variants	  with	  higher	  plasma	  glucose	  and	  insulin,	  and	  waist	  and	  hip	  circumferences[101].	  These	  
strong	  points	  of	  directional	  concordance	  strongly	  suggested	  that	  the	  higher	  T2D	  risk	  caused	  by	  statin	  therapy	  is	  
at	   least	   in	  part	  a	  direct	  consequence	  of	  HMG-­‐CoA	  reductase	  inhibition.	  Importantly,	  however,	  the	  benefits	  of	  
statin	  treatment	  for	  CVD	  prevention	  heavily	  outweigh	  the	  small	  increase	  in	  T2D	  risk.	  
	  
Limitations	  of	  Mendelian	  randomisation	  
Although	  the	  potential	  utility	  of	  MR	  is	  great,	  the	  technique	  is	  not	  without	  limitation.	  Every	  MR	  study	  requires	  a	  
genetic	  instrument	  for	  the	  exposure	  of	  interest,	  and	  in	  some	  instances	  such	  an	  instrument	  may	  be	  unavailable.	  
For	  example,	  genetic	  determinants	  of	  some	  environmental	  or	  behavioural	  exposures	  may	  not	  yet	  have	  been	  
identified,	  or	   a	  GWAS	   from	  which	  MR	   instruments	   could	  be	  derived	  might	  not	  have	  been	   conducted	   for	   an	  
endogenous	   biomarker.	   In	   such	   cases,	   an	  MR	   study	  may	   need	   to	   be	   reconsidered	   or	   postponed.	  Where	   a	  
genetic	  instrument	  is	  available	  it	  may,	  for	  a	  range	  of	  reasons,	  be	  unsuitable.	  Firstly,	  linkage	  disequilibrium	  (LD)	  
between	  variants	  in	  the	  genome	  may	  result	  in	  the	  observed	  effects	  of	  a	  variant	  at	  one	  locus	  being	  confounded	  
by	  the	  linked	  effects	  of	  a	  different,	  possibly	  unidentified	  locus.	  In	  such	  a	  case,	  the	  genetic	  instrument	  is	  said	  to	  
be	   confounded	   by	   LD,	   and	   the	   assumptions	   of	   the	  MR	  model	  may	   be	   violated.	   Differences	   in	   LD	   structure	  
between	   ancestral	   populations	   can	   cause	   such	   confounding	   in	   one	   population	   but	   not	   another.	   Thus,	   MR	  
instruments	  cannot	  be	  assumed	  to	  be	  transferable	  between	  ancestral	  groups	  without	  careful	  evaluation	  of	  the	  
loci	   to	   which	   they	   are	   related	   through	   LD.	   Several	   online,	   open	   access	   tools	   using	   data	   from	   large	   cross-­‐
ancestral	  sequencing	  projects	  are	  now	  available	  for	  such	  evaluation,	  and	  include	  the	  SNP	  Annotation	  and	  Proxy	  
Search	  (SNAP)	  engine	  (http://www.broadinstitute.org/mpg/snap/).	  Finally,	  the	  detrimental	  effects	  of	  a	  variant	  
allocated	  at	  conception	  may	  be	  moderated	  by	  the	  effects	  of	  other	  variants	  along	  the	  lifecourse	  of	  an	  individual	  
in	  order	  to	  reduce	  the	  harm	  caused	  by	  the	  index	  variant.	  This	  process	  is	  known	  as	  canalisation	  and	  can	  lead	  to	  
attenuation	  of	  the	  phenotypic	  effects	  of	  certain	  polymorphisms.	  Such	  phenotypic	  effects	  are	  therefore	  more	  
difficult	  to	  detect	  and	  may	  hamper	  the	  design	  or	  analysis	  of	  an	  MR	  study.	  
	  
Conclusions	  and	  the	  future	  of	  genetic	  research	  in	  CVD	  
Above,	  we	  have	  reviewed	  recent	  progress	  in	  the	  contribution	  of	  genetics	  to	  CVD	  research	  and	  clinical	  practice.	  
With	   the	   field	   swiftly	   advancing,	   new	   developments	   are	   likely	   to	   emerge	   in	   the	   near	   future.	   These	   include	  
pharmacogenetics,	   personalised	   genetic	   testing	   at	   the	   point	   of	   care,	   large-­‐scale	   sequencing	   projects	   and	  
broader	   exploitation	   of	   emerging	   metabolomic,	   proteomic	   and	   transcriptomic	   technologies	   for	   further	  
enhancement	  of	  our	  knowledge	  of	  the	  genetic	  basis	  for	  CVD.	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Figure	  1	  
	  
a.	  Mendelian	  randomisation	  as	  a	  natural	  parallel	  of	   the	  randomised	  controlled	  trial	   (Adapted	  from	  
Hingorani	  AD	  and	  Humphries	  SE	  2005[71].	  	  
b.	  The	  Mendelian	  randomisation	  model.	  In	  order	  to	  infer	  a	  causal	  role	  of	  an	  exposure,	  X,	  in	  a	  disease,	  
Y,	   three	  assumptions	  must	  hold.	  First,	   the	  genetic	   instrument,	  G,	  must	  associate	  with	  X.	  Second,	  G	  
must	  be	  independent	  of	  confounders,	  U,	  of	  the	  X-­‐Y	  relationship.	  Third,	  G	  must	  be	  associated	  with	  Y	  
only	  through	  its	  effect	  on	  X.	  If	  these	  three	  relationships	  can	  be	  demonstrated,	  the	  exposure,	  X,	  can	  
be	  said	  to	  be	  causally	  related	  to	  the	  disease,	  Y.	  
	  Abbreviations:	  RCT	  -­‐	  randomised	  controlled	  trial	  
	   	  
Table	   1.	   Notable	   genetic	   loci	   identified	   by	   meta-­‐analyses	   of	   large	   GWA	   studies	   of	   CHD	   risk	   in	   European	  
populations	  (>63,000	  cases	  and	  >110,000	  controls)[17]	  






P-­‐value	   Remarks	  
SORT1	   1p31.3	   rs602633	   1.13	   1.47	  x	  10−25	   Role	  of	  SORT1	   in	   lipid	  metabolism	  and	  CHD	  
risk	   was	   unrecognised	   until	   reported	   by	  
GWA	  studies[102]	  
	   	   	   	   	   	  
PCSK9	   1p32.2	   rs11206510	   1.04	   1.79	  x	  10–5	   Rare	  PCSK9	  variants	  known	  to	  cause	  familial	  
hypercholesterolaemia	  (FH).	  Drug	   inhibitors	  
of	   PCSK9	   have	   shown	   promise	   in	  
randomised	   trials	   for	   LDL-­‐C	   lowering,	   and	  
data	   are	   awaited	   from	   phase	   III	   trials	   on	  
their	  effects	  on	  CHD	  risk.	  
	   	   	   	   	   	  
SLC22A3-­‐
LPAL2-­‐LPA	  
6q26	   rs3798220	   1.28	   4.90	  x	  10–5	   MR	   studies	   using	   variants	   in	   the	   gene	  
encoding	   lipoprotein(a)	   been	   shown	   Lp(a)	  
to	   have	   a	   causal	   role	   in	   aspects	   of	  
CVD[41,74,74].	  
	   	   	   	   	   	  
LDLR	   19p13.2	   rs1122608	   1.06	   3.72	  x	  10–6	   LDLR	  mutations	  have	   important	   causal	   role	  
in	  FH.	  
	   	   	   	   	   	  
COL4A1-­‐
COL4A2	  
13q34	   rs4773144	  
	  
1.07	   1.43	  x	  10–11	   Encoding	   type	   IV	  collagen,	  COL4A1	   variants	  
have	   also	   been	   associated	   with	   arterial	  
stiffness	  in	  a	  GWA	  study[103]	  
	   	   	   	   	   	  
IL6R	   1q21.3	   rs4845625	   1.06	   3.64	  x	  10–10	   MR	  studies	  have	  demonstrated	  associations	  
of	   variants	   in	   this	   gene	   encoding	   the	  
interleukin-­‐6	   receptor	   with	   CHD	   risk,	   and	  
proposed	  it	  as	  a	  novel	  drug	  target[86,104].	  
	   	   	   	   	   	  
APOB	   2p24.1	   rs515135	   1.07	   2.56	  x	  10–10	   APOB	  mutations	  have	  important	  causal	  role	  
in	  FH.	  
	   	   	   	   	   	  
LPL	   8p21.3	  
	  
rs164	   1.11	   2.88	  x	  10–9	   Variants	  in	  LPL	  (encoding	  lipoprotein	  lipase)	  
have	  been	  associated	  in	  GWA	  studies	  with	  a	  
range	  of	   lipid	  phenotypes,	   including	  HDL-­‐C,	  
triglycerides[23]	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